Hyperfine vs Jin Medical International
Jin Medical International is the larger business, with $20.7m of revenue in fiscal 2025 against $13.6m for Hyperfine (1.5 times as much). Hyperfine grew faster (5.2% against -12.0%). Jin Medical International kept more of each dollar of sales as profit: a net margin of 5.8% against -262.3%.
| Latest fiscal year | HyperfineHYPR, 2025 | Jin Medical InternationalZJYL, 2025 |
|---|---|---|
| Revenue | $13.6m | $20.7m |
| Revenue growth | 5.2% | -12.0% |
| Net income | −$35.6m | $1.2m |
| Operating margin | -273.4% | — |
| Net margin | -262.3% | 5.8% |
| Return on equity | -79.0% | 4.1% |
| Free cash flow | −$29.1m | −$3.7m |
| Cash | $35.1m | $7.5m |
| Total debt | $0 | $18.8m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 102 | — |
| Market value | $72.4m | $344m |
| Price vs our value range | — | — |
| Moat score | 22 (Weak) | — |
| Insider trades, 12 months | 0 buys, 8 sales | 0 buys, 0 sales |